Posted by Michael Wonder on 19 Apr 2020
Knight Therapeutics announces approval of Ibrelsa in Canada
17 April 2020 - Knight Therapeutics announced that Health Canada has approved Ibrelsa (tenapanor) for the treatment of irritable bowel syndrome with constipation in adults.
Knight and Ardelyx signed an agreement in March 2018 granting Knight the exclusive right to distribute Ibrelsa in Canada for irritable bowel syndrome (IBS) and hyperphosphataemia.
Ibrelsa is a minimally-absorbed small molecule that acts locally in the gastro-intestinal tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in an increase in bowel movements and a decrease in abdominal pain for IBS patients.
